CFR Chemaphor Inc.

Thanks to strong turnout at two veterinarian training meetings held recently in Southwestern Ontario, over 100 small animal and horse veterinarians in Canada are now trained and accredited to perform VetStem RC Regenerative Cell Therapy on patients.

VetStem RC Regenerative Cell Therapy is a cutting-edge treatment that captures the natural healing power of an animal's own adipose (fat) tissue. In Canada, procedure training and cell processing is offered to veterinarians through Avivagen Animal Health Inc., a Canadian company dedicated to developing science-based, natural health products for companion animals and offering veterinarians alternatives to traditional treatments.

"Regenerative cell therapy procedures have been used to improve mobility and quality of life in over 8000 companion animals to date," Dr. Corey Orava, keynote speaker at the mid-February training sessions, told veterinarians in attendance. "This is no longer an experimental treatment, but an important tool in the veterinarian's arsenal to improve quality of life in companion animals and return performance animals to full potential," he added. Dr. Orava is Veterinary Services Manager with Vet-Stem, Inc., the company that developed the treatment in the U.S.

VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of arthritic conditions and joint and ligament injuries in dogs, cats and horses. The therapy uses regenerative cells derived from an animal's own adipose tissue. A small amount of fat tissue is extracted by the patient's veterinarian, and then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian laboratory facility. The cells are processed and counted, following stringent sterility and quality assurance guidelines. The number of doses required for the immediate treatment are then returned to the veterinarian for injection into the patient, often within 48 hours of extraction. Extra doses are stored by Avivagen Animal Health for future treatments.

"The seminar was an excellent introduction to the topic of stem cell therapy. Through VetStem RC Regenerative Cell Therapy, Avivagen Animal Health is proving to be on the forefront of stem cell technology," commented Dr. Ian Sandler, a small animal veterinarian with Rosedale Animal Hospital in Toronto, Ontario. "Clearly there are benefits of stem cell therapy for small animals with chronic issues such as arthritis and joint inflammation. There is a certain need for this type of technology and the safety profile appears to be a great option for older dogs and cats. There is definite place for the use of this therapy in our practices and we are looking to initiate this treatment option in many patients."

"Stem cell therapies may now offer new treatments for horses suffering from career ending tendon and ligament damage, as well as potential treatment for osteoarthritis (joint disease)," said Dr. Laura Frost, an equine veterinarian with Halton Equine Veterinary Services in Puslinch, Ontario. "Although there is still a lot that we do not fully understand, there is a strong future for this therapy and I believe we are just at the tip of the iceberg. This is a treatment that can offer true healing rather than merely masking signs of disease."

Avivagen Animal Health is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen Animal Health is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by Avivagen Animal Health for the Canadian animal health market from Vet-Stem (USA).

Chemaphor, a federally incorporated, publicly listed, biotechnology company (TSX Venture Exchange; symbol CFR.v), has core biological and chemistry expertise, focused on the development of nutriscience products.

VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Avivagen Animal Health Inc. David Hankinson CEO 902-825-9270 Chemaphor Inc. Graham Burton, PhD President and Co-Founder 613-990-0969 Evolution Group Inc. 514-448-4887 Toll Free: 866-703-4887 514-906-2428 www.evolutiongrp.com